<DOC>
	<DOCNO>NCT00002241</DOCNO>
	<brief_summary>The purpose study see whether take indinavir ( IDV ) plus ritonavir ( RTV ) plus stavudine ( d4T ) plus lamivudine ( 3TC ) 2 time day safe low level HIV blood .</brief_summary>
	<brief_title>Safety Effectiveness Anti-HIV Drug Combination Taken Twice Daily</brief_title>
	<detailed_description>Patients take IDV plus RTV plus d4T plus 3TC twice daily 24 week . Every 4 week , patient physical exams laboratory test blood urine , CD4 cell count plasma viral RNA measure . At Week 24 , proportion patient plasma viral RNA 400 copies/ml determine identify clinically meaningful antiretroviral activity drug regimen . An observed response proportion 80 % high consider clinically meaningful .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Have CD4 cell count 75 cells/mm3 viral load 5,000 copies/ml . Are age 16 older ( consent parent guardian require 18 ) . Agree practice abstinence use barrier method birth control ( condom ) . Are willing stop take antiHIV drug except study drug . ( Patients may able continue take drug infection . ) Exclusion Criteria Patients eligible study : Have cancer , lung disease , severe hepatitis , active AIDSrelated infection . ( Certain AIDSrelated infection Kaposi 's sarcoma may allow ) . Have ever take 3TC , abacavir ( ABC ) , protease inhibitor ( IDV RTV ) . Have change medication last 2 week . Are allergic IDV , RTV , d4T , 3TC . Have use certain medication ( see technical summary detail ) . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2001</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>